RNA BASED THERAPIES

RNA-based therapies use RNA molecules to modulate biological pathways, offering temporary, precise treatments without altering DNA. Applications include correcting genetic mutations (ADAR enzymes), bypassing stop-codon mutations (suppressor tRNAs), and treating diseases like cystic fibrosis (PTC124) and spinal muscular atrophy (ASOs). India needs genetic research and infrastructure to adopt these therapies for inherited retinal diseases.

Last Updated on 4th February, 2025
3 minutes, 39 seconds

Description

Copyright infringement not intended

Picture Courtesy: The Hindu

Context:

According to the World Health Organisation, more than 2.2 billion people worldwide experience some form of vision impairment, including inherited retinal diseases (IRDs).  

About Inherited Retinal Diseases (IRDs)

Inherited retinal diseases (IRDs) are a group of genetic conditions that affect the retina and can lead to vision loss or blindness. IRDs are rare but can affect people of all ages. 

Symptoms Difficulty seeing in the dark or dim, Reduced side vision, Glare and difficulty in bright light, Reduced central vision, and Difficulty seeing colors or differences between colors. 

RNA-based therapies considered promising for treating IRDs

RNA-based therapies offer a precise, temporary way to correct genetic defects without altering DNA.

Approaches like antisense oligonucleotides (ASOs), ADAR RNA editing, suppressor tRNAs, and PTC124 bypass mutations or restore protein production in retinal cells.

These methods avoid risks associated with permanent DNA changes and have already shown success in treating spinal muscular atrophy and cystic fibrosis.

Is India ready to adopt RNA-based precision therapies for IRDs?

Global advancements are encouraging, however the country lacks large-scale genetic studies to map IRD mutations in its diverse population.

Without data on prevalent mutations—like the ABCA4 gene’s role in Indian subgroups—researchers cannot design targeted therapies.

Limited awareness among clinicians, scarce genetic counseling, and uneven diagnostic infrastructure further hinder progress.

What steps can India take to harness RNA therapeutics for retinal diseases?

  • Prioritize genetic research: Conduct nationwide studies to map IRD mutations.
  • Boost collaborations: Partner institutions like CSIR-IGIB and L.V. Prasad Eye Institute to accelerate therapy development.
  • Invest in infrastructure: Expand access to genetic testing and counseling, especially in rural areas.
  • Raise awareness: Train clinicians about RNA therapies and their potential.

Must Read Articles: 

GENE EDITING FOR EYE DISEASES

Source: 

THE HINDU 

PRACTICE QUESTION

Q.In the question given below, there are two statements marked as Assertion (A) and Reason (R).

Assertion: RNA-based therapies are considered safer than DNA-based therapies.

Reason: RNA-based therapies make temporary changes that do not alter the genome permanently.

Which of the options given below is correct? 

A) Both A and R are true, and R is the correct explanation for A.

B) Both A and R are true, but R is not the correct explanation for A.

C) A is true, but R is false.

D) A is false, but R is true.

Answer: A

Explanation:

The assertion is true: RNA-based therapies are safer than DNA-based therapies.

The reason is also true and correctly explains the assertion: RNA-based therapies make temporary changes and do not alter the genome permanently.

Related Articles

SILICON CARBIDE 04 Feb, 2025
F11 BACTERIA 03 Feb, 2025
ORGANOPHOSPHATE 31 Jan, 2025
ASTEROIDS 31 Jan, 2025
DEEPSEEK 30 Jan, 2025
FENTANYL 29 Jan, 2025
NSV 02 28 Jan, 2025
PARAQUAT 28 Jan, 2025

Free access to e-paper and WhatsApp updates

Let's Get In Touch!